Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Each patch has 1 % GHK-Cu in 2 g gel reservoir
Nucleotide sequence and expression of the selenocysteine containing polypeptide of formate dehydrogenase (formate-hydrogen-lyase-linked) from Escherichia coli
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
CJC-1295 without DAC: Short Half-Life: Approximately 30 minutes, requiring more frequent administration
US$ 23.76
US$ 25.93
US$ 24.34
US$ 22.60
US$ 23.50
US$ 27.48
